The Next Generation of ImmunoTherapy
 
NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. The AIM technology provides an important advance in the development of immuno-therapies for a variety of cancers and other diseases.


The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cells (APC). Natural APC are major players in the body’s immune system as they direct the immune system cells in attacks on specifically targeted antigens and cells. However, under certain disease conditions, natural APC can be damaged, absent or inactive.

 


Central to the AIM technology is the artificial Antigen Presenting Cell (aAPC) which in its basic form has four components: the nanoparticle that serves as a synthetic cellular core; recombinant HLA-Ig dimer molecules that “present” a specific antigen to T cells; the antigen to stimulate a specific T cell response; and a co-stimulatory molecule that facilitates activation of T cells.

 

The AIM technology holds great potential for use in immuno-therapy because aAPC can be readily engineered in such a way that a highly specific immune attack can be directed toward any foreign substance or cell type in a patient’s body. 

NexImmune executives will attend the JP Morgan Healthcare Conference on January 12-15, 2015 in San Francisco, California.  


NexImmune Announces $3 Million Financing 

Funding will support the development of AIM 101, a novel immuno-therapeutic agent for cancer


NexImmune’s AIMä Immunotherapy Technology

Enables Novel Adoptive Immuno-therapy Approach for the Treatment of Cancer

SBIR Grant
July 2013 - NexImmune received an SBIR grant of $290,000 from the NIH for the development of a human therapeutic based on AIM Technology.